HC Wainwright Issues Pessimistic Forecast for Curis (NASDAQ:CRIS) Stock Price

Curis (NASDAQ:CRIS) had its price objective decreased by stock analysts at HC Wainwright from $20.00 to $16.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock.

Separately, StockNews.com assumed coverage on shares of Curis in a report on Saturday. They issued a “hold” rating for the company.

Curis Stock Performance

Shares of NASDAQ CRIS traded down $0.17 during midday trading on Monday, reaching $2.15. 34,847 shares of the company traded hands, compared to its average volume of 58,937. Curis has a 12 month low of $2.15 and a 12 month high of $17.49. The stock’s 50-day simple moving average is $3.04 and its 200-day simple moving average is $3.88. The firm has a market cap of $18.20 million, a PE ratio of -0.28 and a beta of 3.49.

Institutional Investors Weigh In On Curis

Several institutional investors and hedge funds have recently bought and sold shares of the company. Focused Wealth Management Inc boosted its stake in Curis by 9.5% in the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 5,138 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Curis during the 4th quarter valued at approximately $35,000. Millennium Management LLC increased its position in Curis by 92.6% during the 4th quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 12,287 shares in the last quarter. Geode Capital Management LLC lifted its stake in Curis by 27.3% in the 4th quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 17,820 shares during the last quarter. Finally, M28 Capital Management LP boosted its position in Curis by 23.5% in the fourth quarter. M28 Capital Management LP now owns 521,059 shares of the biotechnology company’s stock valued at $1,594,000 after buying an additional 99,108 shares in the last quarter. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.